UroGen Receives New U.S. Patent Allowance For Next-Generation Mitomycin-Based Products Expected To Provide Protection Until December 2041
Portfolio Pulse from Benzinga Newsdesk
UroGen Pharma Ltd. has received a Notice of Allowance from the USPTO for a new patent covering its RTGel® technology combined with medac's mitomycin formulation. This patent, once issued, will protect UroGen's UGN-103 and UGN-104 programs until December 2041, targeting specific urothelial cancers.

September 16, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UroGen Pharma has received a Notice of Allowance for a new U.S. patent covering its RTGel® technology with medac's mitomycin formulation, protecting its UGN-103 and UGN-104 programs until December 2041. This strengthens UroGen's intellectual property and could enhance its market position in treating specific urothelial cancers.
The new patent allowance provides long-term intellectual property protection for UroGen's key cancer treatment programs, potentially enhancing its competitive edge and market position. This is likely to positively impact URGN's stock price in the short term as it secures a significant asset for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100